185 related articles for article (PubMed ID: 35734415)
1. Impact of National Volume-Based Procurement on the Procurement Volumes and Spending for Antiviral Medications of Hepatitis B Virus.
Yuan J; Lu ZK; Xiong X; Lee TY; Huang H; Jiang B
Front Pharmacol; 2022; 13():842944. PubMed ID: 35734415
[No Abstract] [Full Text] [Related]
2. Impact of China's National Volume-Based Procurement on Drug Procurement Price, Volume, and Expenditure: An Interrupted Time Series Analysis in Tianjin.
Zhao B; Wu J
Int J Health Policy Manag; 2023; 12():7724. PubMed ID: 38618801
[TBL] [Abstract][Full Text] [Related]
3. The impact of "4 + 7" volume-based drug procurement on the volume, expenditures, and daily costs of antihypertensive drugs in Shenzhen, China: an interrupted time series analysis.
Yang Y; Tong R; Yin S; Mao L; Xu L; Hao S; Mao Z
BMC Health Serv Res; 2021 Nov; 21(1):1275. PubMed ID: 34823516
[TBL] [Abstract][Full Text] [Related]
4. Effects of volume-based procurement policy on the usage and expenditure of first-generation targeted drugs for non-small cell lung cancer with EGFR mutation in China: an interrupted time series study.
Wang X; Huang H; Sun Y; Zhu Z; Jiang B; Yang L
BMJ Open; 2023 Jul; 13(7):e064199. PubMed ID: 37407064
[TBL] [Abstract][Full Text] [Related]
5. A quasi-experimental study of the volume-based procurement (VBP) effect on antiviral medications of hepatitis B virus in China.
Wen X; Xu L; Chen X; Wu R; Luo J; Wan Y; Mao Z
Front Pharmacol; 2023; 14():984794. PubMed ID: 37731741
[No Abstract] [Full Text] [Related]
6. Impacts of national volume-based drug procurement policy on the utilization and costs of antihypertensive drugs in a Chinese medicine hospital: an interrupted time series analysis of 5138 patients.
Shang L; Cheng Y; Zhou J; Bao Y; Kong D; Huang R; Chen Y; Wang H; Gu N; Ma A
Front Pharmacol; 2024; 15():1302154. PubMed ID: 38389928
[No Abstract] [Full Text] [Related]
7. Lowering drug prices and enhancing pharmaceutical affordability: an analysis of the national volume-based procurement (NVBP) effect in China.
Yuan J; Lu ZK; Xiong X; Jiang B
BMJ Glob Health; 2021 Sep; 6(9):. PubMed ID: 34518200
[TBL] [Abstract][Full Text] [Related]
8. National Volume-Based Procurement (NVBP) exclusively for insulin: towards affordable access in China and beyond.
Yuan J; Li M; Jiang X; Lu ZK
BMJ Glob Health; 2024 Jan; 9(1):. PubMed ID: 38232994
[TBL] [Abstract][Full Text] [Related]
9. Improving access to medicines and beyond: the national volume-based procurement policy in China.
Zhu Z; Wang Q; Sun Q; Lexchin J; Yang L
BMJ Glob Health; 2023 Jul; 8(7):. PubMed ID: 37463786
[TBL] [Abstract][Full Text] [Related]
10. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China.
Zhang Y; Wushouer H; Han S; Fu M; Guan X; Shi L; Wagner A
BMJ Glob Health; 2021 Jul; 6(7):. PubMed ID: 34266848
[TBL] [Abstract][Full Text] [Related]
11. Impact of National Centralized Drug Procurement Policy on Antiviral Utilization and Expenditure for Hepatitis B in China.
Zhao X; Li M; Wang H; Xu X; Wu X; Sun Y; Ning C; Wang B; Chen S; You H; Jia J; Kong Y
J Clin Transl Hepatol; 2022 Jun; 10(3):420-428. PubMed ID: 35836769
[TBL] [Abstract][Full Text] [Related]
12. Patients' attitudes towards switching to national volume-based procurement (NVBP) Drugs-a qualitative investigation in Wuhan, China.
Tao J; Li S; Xu Q; Gong S; Zeng F
BMC Health Serv Res; 2023 Jan; 23(1):62. PubMed ID: 36670463
[TBL] [Abstract][Full Text] [Related]
13. The impact of Chinese volume-based procurement on pharmaceutical market concentration.
Yang Y; Liu Y; Mao Z; Mao J; Jin Y
Front Pharmacol; 2024; 15():1386533. PubMed ID: 38895618
[TBL] [Abstract][Full Text] [Related]
14. The pan-Canadian Tiered Pricing Framework and Chinese National Volume-Based Procurement: A comparative study using Donabedian's structure-process-outcome framework.
Wang Q; Liu S; Nie Z; Zhu Z; Fu Y; Zhang J; Wei X; Yang L; Wei X
J Glob Health; 2023 Nov; 13():04137. PubMed ID: 37947028
[TBL] [Abstract][Full Text] [Related]
15. The impacts of Chinese drug volume-based procurement policy on the use of policy-related antibiotic drugs in Shenzhen, 2018-2019: an interrupted time-series analysis.
Yang Y; Chen L; Ke X; Mao Z; Zheng B
BMC Health Serv Res; 2021 Jul; 21(1):668. PubMed ID: 34238290
[TBL] [Abstract][Full Text] [Related]
16. Impact of '4+7' volume-based drug procurement on the use of policy-related original and generic drugs: a natural experimental study in China.
Wang J; Yang Y; Xu L; Shen Y; Wen X; Mao L; Wang Q; Cui D; Mao Z
BMJ Open; 2022 Mar; 12(3):e054346. PubMed ID: 35288385
[TBL] [Abstract][Full Text] [Related]
17. Impacts of adjustment of National Reimbursement Drug List on orphan drugs volume and spending in China: an interrupted time series analysis.
Yi H; Shi F; Wang Z; Kuai L; Xu D; Xie Y; Xing H
BMJ Open; 2023 Oct; 13(10):e064811. PubMed ID: 37852769
[TBL] [Abstract][Full Text] [Related]
18. Changing Characteristics of Pharmaceutical Prices in China Under Centralized Procurement Policy: A Multi-Intervention Interrupted Time Series.
Long H; Yang Y; Geng X; Mao Z; Mao Z
Front Pharmacol; 2022; 13():944540. PubMed ID: 35910351
[No Abstract] [Full Text] [Related]
19. The impact of the national volume-based procurement policy on the use of policy-related drugs in Nanjing: an interrupted time-series analysis.
Wang X; He X; Zhang P; Zhang M; Ma R; Dai R; Li X
Int J Equity Health; 2023 Sep; 22(1):200. PubMed ID: 37770924
[TBL] [Abstract][Full Text] [Related]
20. Impact of the National Centralized Drug Procurement Policy (4 + 7 policy) on the drug expenditures of patients treated in outpatient and emergency departments in a large tertiary level-A hospital in China: A single centre, interrupted time series.
Lan T; Guan L; Pang X; Li X; Yu Q
J Clin Pharm Ther; 2022 Jan; 47(1):104-111. PubMed ID: 34668203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
